Merkel cell carcinoma adjuvant therapy: Current data support radiation but not chemotherapy

University of Washington Seattle, Seattle, Washington, United States
Journal of the American Academy of Dermatology (Impact Factor: 5). 08/2007; 57(1):166-9. DOI: 10.1016/j.jaad.2007.03.011
Source: PubMed

ABSTRACT Merkel cell carcinoma (MCC) is a skin cancer with 30% mortality and an incidence that has tripled in the past 15 years. There is agreement that surgical excision with negative margins is an appropriate therapeutic first step and that sentinel lymph node biopsy is a powerful prognostic indicator. After excision of detectable cancer, optimal adjuvant therapy is not well established. A role for adjuvant radiotherapy is increasingly supported by observational data. These data suggest that a regimen of surgery plus adjuvant radiotherapy is associated with both a lower loco-regional recurrence rate and longer overall survival when compared with surgery alone. In contrast, a role for adjuvant chemotherapy is not well supported. The rationale for chemotherapy in this disease is based on small-cell lung cancer, a more common neuroendocrine tumor for which chemotherapy is the primary treatment modality. Several issues call into question the routine use of adjuvant chemotherapy in MCC: lack of evidence for improved survival; the associated morbidity and mortality; important differences between small-cell lung cancer and MCC; and rapid development of resistance to chemotherapy. Importantly, chemotherapy suppresses immune function that plays an unusually large role in defending the host from the development and progression of MCC. Taken together, these arguments suggest that adjuvant radiation may be indicated for many MCC patients while adjuvant chemotherapy should largely be restricted to clinical trials.

Download full-text


Available from: Paul Nghiem, Jul 02, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionViscum album L. extracts (VAEs) are widely used in the complementary treatment of cancer, to improve quality of life of cancer patients, commonly using subcutaneous application of low doses of VAEs.
    European Journal of Integrative Medicine 06/2010; 2(2):63-69. DOI:10.1016/j.eujim.2010.04.001
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: El objetivo de este artículo es comunicar un caso de carcinoma de células de Merkel de la piel. Este tumor es también conocido como carcinoma trabecular o carcinoma indiferenciado de células pequeñas de la piel. Es un tumor poco frecuente pero con características bien definidas y tratamiento estandarizado, con buena supervivencia de los pacientes que son diagnosticados acertadamente por estudios histopatológicos. 63-69 bimestral The aim of this article is to report a case of Merkel cell carcinoma of the skin. This tumor is also known as carcinoma trabecular or small cell undifferentiated carcinoma of the skin. It is an uncommon tumor but with well-defined characteristics and standardized treatment, with good survival in patients who are accurately diagnose by histological studies.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma that originates in the skin. Epidemiological factors strongly associated with MCC are: age over 65 years, fair skin, history of extensive sun exposure and chronic immune suppression. The literature is sparse and many questions currently remain unanswered regarding optimal treatment of MCC. To provide clinical practice guidelines for the diagnosis and treatment of MCC. Literature data were analysed and the existing German and American practice guidelines were compared. Where German and US guidelines were identical, the recommendations in question were adopted. Regarding discordant points, a formalized consensus process was devised. The guidelines were then written by an editorial group and validated by the cutaneous oncology group of the French Society of Dermatology. The guidelines were drawn up according to three levels of scientific evidence: a: complete agreement between the German and American guidelines; b: results of the formalized consensus process; c: expert opinion of the steering group based on available evidence. Our guidelines present up-to-date recommendations on clinical and pathological procedures for diagnosis, staging, surgical treatment, sentinel lymph node biopsy, radiotherapy and follow-up. We created a set of diagnostic and treatment guidelines in order to standardize management of MCC, which may be not optimal throughout France.
    Annales de Dermatologie et de Vénéréologie 138(6-7):475-82.